Progressive Worsening of Adaptive Functions in Down Syndrome May Be Mediated By the Complexing of Soluble Aβ Peptides With the α7 Nicotinic Acetylcholine Receptor: Therapeutic Implications
- 1 September 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 26 (5) , 277-283
- https://doi.org/10.1097/00002826-200309000-00013
Abstract
In persons with Down syndrome, soluble Abeta peptides, which result from the processing of the amyloid precursor protein, appear in the brain decades before the extracellular deposition of neuritic plaques. These soluble amyloidogenic peptides accumulate intraneuronally and can be secreted extracellularly. Their appearance has been reported in the brains of fetuses with Down syndrome. The extra gene dosage effect associated with trisomy 21 results in abnormalities of the processing of amyloid precursor protein in persons with Down syndrome. Abeta peptides, especially Abeta1-42, have been shown to form tight complexes with the alpha7 nicotinic acetylcholine receptor, interfering with transduction of the acetylcholine signal by this nicotinic receptor subtype. Furthermore, the selective binding of Abeta peptides by this nicotinic acetylcholine receptor subtype is associated with cytotoxicity. The alpha7 nicotinic acetylcholine receptor has unique electrophysiologic properties and plays a prominent role in normal psychophysiologic processes (eg, sensory inhibition) and cognition. In persons with Down syndrome there is a decrease in the ability to perform instrumental activities of daily living that worsen with aging. The progressive worsening of adaptive functions and cognition in persons with Down syndrome may be, at least in part, mediated by interference with this receptor by soluble Abeta peptides. In view of this complex formed by soluble Abeta peptides and the alpha7 nicotinic acetylcholine receptor, cholinergic interventions that have been developed for Alzheimer disease, including selective nicotinic ones, should be explored in Down syndrome. Ideally, selective cholinergic interventions would slow the progression of the worsening of adaptive function and emergence of dementia in persons with Down syndrome.Keywords
This publication has 26 references indexed in Scilit:
- Choline and acetylcholine have similar kinetic properties of activation and desensitization on the α7 nicotinic receptors in rat hippocampal neuronsBrain Research, 2000
- Neuronal nicotinic acetylcholine receptors: from the gene to the diseaseBehavioural Brain Research, 2000
- Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and SchizophreniaJournal of Neurochemistry, 1999
- The α7 nicotinic acetylcholine receptor in neuronal plasticityMolecular Neurobiology, 1999
- Contribution of nicotinic receptors to the function of synapses in the central nervous system: The action of choline as a selective agonist of α7 receptorsJournal of Physiology-Paris, 1998
- Allosteric nicotinic receptors, human pathologiesJournal of Physiology-Paris, 1998
- Schizophrenia, Sensory Gating, and Nicotinic ReceptorsSchizophrenia Bulletin, 1998
- Choline is a Selective Agonist of α7 Nicotinic Acetylcholine Receptors in the Rat Brain NeuronsEuropean Journal of Neuroscience, 1997
- Nicotinic acetylcholine receptors in health and diseaseMolecular Neurobiology, 1997
- Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophreniaBiological Psychiatry, 1995